Ep. 7 - Heading to Houston: What We're Looking Forward to at ASN Kidney Week 2025 (with Dr. Pietro Canetta) episode artwork

EPISODE · Nov 3, 2025 · 46 MIN

Ep. 7 - Heading to Houston: What We're Looking Forward to at ASN Kidney Week 2025 (with Dr. Pietro Canetta)

from Biotech Matters · host Jeff Fineberg, PhD and Pietro Canetta, MD

Bluestar is once again heading to ASN Kidney Week, this time in Houston, TX. Since our last episode, Otsuka, the manufacturer of sibeprenlimab, announced that the FDA has granted Priority Review of their BLA application; its PDUFA date is November 28th of this year. Additionally, Vera Therapeutics, the manufacturer of atacicept put out a press release this past summer that the ORIGIN Phase 3 trial met its primary endpoint of reduction in proteinuria (UPCR); participants receiving atacicept achieved a 46% reduction from baseline, and 42% reduction compared to placebo at week 36 (pth, 2026. After the 2023 conference, Dr. Pietro Canetta joined Bluestar Principal Jeff Fineberg on the Biotech Matters podcast to talk about all things IgAN, as well as the two FILSPARI trials and the data presented at the conference. So, it's only fitting that Dr. Canetta is back on the podcast to revisit that conversation, discuss what has happened in the two years since, and tell us what he's most looking forward to at this year's conference. Where to find Dr. Canetta: Columbia University Glomerular Center Where to learn more: Columbia CME Courses Glomerular Disease-Focused CME Course Topics and Timestamps 00:00 - Intro + recap 04:00 - Reflection on Filspari in FSGS; implications for UPCR in FSGS and other diseases going forward 12:40 - DKD: better/newer surrogate endpoints; matching patients to the right Tx 19:30 - IgAN: the 4-hit model of disease and the role of B cells 22:45 - Where do B cell-targeting therapies fit in the evolving IgAN Tx Paradigm? 26:45 - The counter argument to using Bcells early in IgAN treatment 30:10 - Bcells beyond IgAN: Lupus Nephritis and other glomerular diseases 33:00 - Different B cell-targeting mechanisms for different glomerular diseases and/or heterogeneous patient populations 36:45 - A homecoming for complement inhibitor therapies 42:00 - Other recommended sessions at Kidney Week 2025 45:00 - Where to learn more from Dr. Canetta

NOW PLAYING

Ep. 7 - Heading to Houston: What We're Looking Forward to at ASN Kidney Week 2025 (with Dr. Pietro Canetta)

0:00 46:54

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Hyperfluent Hypio Hyperfluent transmits straight from the heart of Hyperliquid, where culture, creativity, and capital converge. Anchored by the architects of Hypio—the decentralized cultural virus—each episode archives the minds engineering the blockchain built to house all finance. These conversations are traceable artifacts in HyperEVM’s evolution: not just what’s being built, but why it matters, how it mutates, and where it’s taking us next. Listen in for the blueprints, the blind spots, and the narrative weapons shaping tomorrow’s markets.Hyperfluent: learn the language, ride the wave, spread the strain. Mobile Money by moomoo Mobile Money by moomoo Hear from seasoned traders, financial influencers, and industry insiders as they discuss money matters and market news and share their personal finance stories.Disclaimers: https://www.moomoo.com/us/support/topic4_523 Somali Motivation podcast Istahil Aideed At the heart of the Somali Motivation Podcast lies a profound mission: to uplift, inspire, and catalyze personal growth in the lives of our listeners. With a steadfast dedication to mental health awareness and domestic abuse awareness, our podcast embraces vulnerability, encourages healing, and fosters resilience within the Somali community and beyond. Through heartfelt conversations, expert insights, and shared experiences, we create a warm and welcoming space where every voice matters. Join our transformative journey as we embark on a quest to empower our community, spark meaningful change, and weave a tapestry of hope and strength. Together, we can make a difference, one episode at a time. The Up and to the Right | Small Business | Practical, Actionable, Sustainable Improvements beyond50percent Welcome to Up and to the Right, the no-nonsense podcast where we blend your passion with proven business principles and practical tips, empowering you to create the impact and success you envision.Hosted by Stephen Krausse, the show covers what matters to small business owners, startups, and people interested in becoming entrepreneurs. No buzzwords and no hyped-up trends!A graduate of Colorado State University's College of Business, Stephen has an academic background that compliments over 25 years of business operations and management experience. He started his first business as a freshman in college in 1987, recording and producing demo tapes for local bands. Since that time, he’s been involved with numerous successful small businesses, including the operation and management of a niche high-tech company with customers and suppliers worldwide.As a business professional by education and trade, he works with select business owners to blend their passion with proven principles, givi

Frequently Asked Questions

How long is this episode of Biotech Matters?

This episode is 46 minutes long.

When was this Biotech Matters episode published?

This episode was published on November 3, 2025.

What is this episode about?

Bluestar is once again heading to ASN Kidney Week, this time in Houston, TX. Since our last episode, Otsuka, the manufacturer of sibeprenlimab, announced that the FDA has granted Priority Review of their BLA application; its PDUFA date is November...

Can I download this Biotech Matters episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!